Publications and presentations

AVEO Oncology allows you to access a number of published papers and presentations outlining our clinical data that were given at premier conferences and symposia around the world.

June 7, 2011
PresentationTivozanib

ASCO 2011: Final Analysis of the Phase 2 Randomized Discontinuation Trial of Tivozanib (AV-951) Versus Placebo in Patients With Renal Cell Carcinoma

June 7, 2011
PresentationTivozanib

ASCO 2011: Results From a Phase 1 Trial of Tivozanib (AV-951) Combined With Temsirolimus Therapy in Patients With Renal Cell Carcinoma

June 6, 2011
PresentationFiclatuzumab

ASCO 2011: Phase 2 Study of Ficlatuzumab (AV-299), an Anti-Hepatocyte Growth Factor Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With Non–Small Cell Lung Cancer

June 4, 2011
PresentationFiclatuzumab

ASCO 2011: Phase 1b Study of Ficlatuzumab (AV-299), an Anti-Hepatocyte Growth Factor Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC

February 12, 2011
PublicationTivozanib

Development of second-generation VEGFR tyrosine kinase inhibitors: Current status

Authors: Pankaj Bhargava, Murray O. Robinson. Click here for link to article.

November 19, 2010
PresentationTivozanib

EORTC-NCI-AACR 2010: Tivozanib Biomarker Identifies Tumor-infiltrating Myeloid Cells Contributing to Tivozanib Resistance in Both Preclinical Models and Human Renal Cell Carcinoma

1 … 11 12 13 14

Looking for medical information? Contact our Medical Information Team at

AVEOmedicalinformation@aveooncology.com.